Tempol -C (codeine + paracetamol + caffeine): Uses, Dosage & Side Effects

What it's for (Indications)

This combination medication, containing codeine, paracetamol (acetaminophen), and caffeine, is indicated for the short-term relief of acute, moderate pain that is not relieved by paracetamol, ibuprofen, or aspirin alone.
Its primary use is in situations where a more potent analgesic effect is required, but an opioid-only medication is not warranted.
Common indications include the management of various types of pain such as headaches, including tension headaches and migraines, dental pain (e.
g.
, toothache, post-extraction pain), musculoskeletal pain (e.
g.
, backache, sprains, strains), dysmenorrhoea (menstrual pain), and post-operative pain.
It may also be used to reduce fever associated with painful conditions.
Due to the codeine component, its use should be limited to the shortest duration necessary, typically not exceeding three days, to mitigate risks associated with opioid analgesics.
The inclusion of caffeine is often aimed at enhancing the analgesic effect and counteracting potential sedation from codeine.
This formulation is generally reserved for adults and adolescents aged 12 years and older when other simpler analgesics have proven insufficient, with specific age-related restrictions for codeine use.

Dosage Information

Type	Guideline
Standard	The typical adult dosage for this combination product (e.g., Febricod-C) generally involves taking one or two tablets every 4 to 6 hours as needed for pain relief. Each tablet commonly contains a specific fixed dose of paracetamol (e.g., 500 mg), codeine (e.g., 8 mg or 15 mg), and caffeine (e.g., 30 mg). The maximum daily dose of paracetamol should not exceed 4000 mg (4 grams) over a 24-hour period, considering all paracetamol-containing products. For codeine, the maximum daily dose typically should not exceed 240 mg. It is crucial not to exceed the recommended dosages and to maintain adequate dosing intervals to prevent potential overdose and severe adverse effects, particularly paracetamol-induced hepatotoxicity. This medication is intended for short-term use only, usually for no more than three consecutive days, due to the risk of opioid dependence and medication overuse headache. Patients should always consult a healthcare professional for personalized dosage recommendations, especially those with pre-existing conditions or those taking other medications. Administration with food or milk may help reduce gastrointestinal discomfort.

Type

Guideline

Standard

The typical adult dosage for this combination product (e.g., Febricod-C) generally involves taking one or two tablets every 4 to 6 hours as needed for pain relief. Each tablet commonly contains a specific fixed dose of paracetamol (e.g., 500 mg), codeine (e.g., 8 mg or 15 mg), and caffeine (e.g., 30 mg). The maximum daily dose of paracetamol should not exceed 4000 mg (4 grams) over a 24-hour period, considering all paracetamol-containing products. For codeine, the maximum daily dose typically should not exceed 240 mg. It is crucial not to exceed the recommended dosages and to maintain adequate dosing intervals to prevent potential overdose and severe adverse effects, particularly paracetamol-induced hepatotoxicity. This medication is intended for short-term use only, usually for no more than three consecutive days, due to the risk of opioid dependence and medication overuse headache. Patients should always consult a healthcare professional for personalized dosage recommendations, especially those with pre-existing conditions or those taking other medications. Administration with food or milk may help reduce gastrointestinal discomfort.

Safety & Warnings

Common Side Effects

The use of this combination medication can lead to a range of side effects, stemming from its individual components.
Common side effects associated with the codeine component include constipation, nausea, vomiting, dizziness, drowsiness, sedation, and lightheadedness.
Less common but more severe opioid-related side effects can include respiratory depression, hypotension, urinary retention, pruritus (itching), and mood changes.
Due to caffeine, patients may experience nervousness, restlessness, insomnia, palpitations, and gastrointestinal upset.
Paracetamol, while generally well-tolerated at therapeutic doses, can cause nausea, vomiting, and abdominal pain.
The most serious side effect of paracetamol is hepatotoxicity (liver damage), which can occur with overdose and, rarely, at therapeutic doses in susceptible individuals.
Other rare but serious paracetamol-related adverse reactions include severe skin reactions (e.
g.
, Stevens-Johnson Syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis) and blood dyscrasias (e.
g.
, neutropenia, pancytopenia).
Prolonged or excessive use of combination analgesics, particularly those containing codeine and caffeine, may also lead to medication overuse headaches or withdrawal symptoms upon discontinuation.
Patients experiencing any severe or persistent side effects should seek immediate medical attention.

Serious Warnings

Black Box Warning: WARNING: RISK OF ADDICTION, ABUSE, MISUSE, RESPIRATORY DEPRESSION, CYP2D6 ULTRA-RAPID METABOLISM, NEONATAL OPIOID WITHDRAWAL SYNDROME, AND HEPATOTOXICITY. Codeine, an opioid agonist and a component of Febricod-C, exposes patients and other users to the serious risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Prior to initiating treatment, assess each patient's risk of addiction, abuse, or misuse, and monitor all patients regularly for the development of these behaviors or conditions. Serious, life-threatening, or fatal respiratory depression may occur with the use of codeine-containing products. Patients must be monitored closely, especially during initiation of therapy or following a dose increase. Accidental ingestion of even a single dose of this product, especially by children, can result in a fatal overdose of codeine. **CYP2D6 Ultra-Rapid Metabolism of Codeine:** Individuals who are ultra-rapid metabolizers of codeine due to a specific CYP2D6 genetic polymorphism convert codeine into its active metabolite, morphine, more rapidly and completely than other people. This can result in dangerously high serum morphine levels, which may lead to life-threatening or fatal respiratory depression. This risk is particularly elevated in children who receive codeine after tonsillectomy and/or adenoidectomy, and in breastfeeding mothers, potentially causing serious adverse reactions in breastfed infants. Consequently, Febricod-C is contraindicated in these populations. **Neonatal Opioid Withdrawal Syndrome (NOWS):** Prolonged use of this product during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated. This condition requires management according to protocols developed by neonatology experts and should involve appropriate medical care and social support. **Concomitant Use with Central Nervous System Depressants:** Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Prescribe concomitant CNS depressants only for patients for whom alternative treatment options are inadequate, and use the lowest effective dosages and shortest possible durations. **Hepatotoxicity:** Paracetamol, a component of Febricod-C, has been associated with cases of acute liver failure, sometimes resulting in liver transplant and death. Most cases of liver injury are associated with the use of paracetamol at doses exceeding 4,000 mg per day and often involve more than one paracetamol-containing product. To minimize this risk, ensure that the total daily dose of paracetamol from all sources does not exceed the recommended maximum of 4,000 mg in adults, and educate patients on avoiding concurrent use of other paracetamol-containing products.
This combination product carries significant warnings due to its active ingredients.
**Codeine** poses risks of addiction, abuse, and misuse, which can lead to overdose and death.
It can cause serious, life-threatening respiratory depression, particularly in patients who are ultra-rapid metabolizers of CYP2D6, or in children following tonsillectomy or adenoidectomy, for whom it is contraindicated.
Codeine is also contraindicated in children younger than 12 years of age and in breastfeeding mothers due to the risk of infant exposure to high levels of morphine.
Concomitant use with other central nervous system depressants, including alcohol, benzodiazepines, and other opioids, can result in profound sedation, respiratory depression, coma, and death.
**Paracetamol** overdose can lead to severe, potentially fatal hepatotoxicity; patients must be warned not to exceed the maximum daily dose and to avoid concomitant use of other paracetamol-containing products.
Severe skin reactions, though rare, have been reported with paracetamol.
**Caffeine** can exacerbate anxiety, cause sleep disturbances, and lead to cardiovascular effects like palpitations in sensitive individuals or at high doses.
This medication should be used with extreme caution in patients with pre-existing respiratory conditions (e.
g.
, asthma, COPD), head injury, increased intracranial pressure, gastrointestinal obstruction (e.
g.
, paralytic ileus), severe hepatic or renal impairment, or a history of substance abuse.
Patients should be advised against driving or operating heavy machinery due to potential drowsiness or dizziness.
Withdrawal symptoms may occur upon abrupt discontinuation after prolonged use.
Pregnancy and lactation require careful consideration due to potential risks to the fetus and infant.

How it Works (Mechanism of Action)

This medication combines three distinct pharmacological agents to provide comprehensive pain relief. **Paracetamol (Acetaminophen)** exerts its analgesic and antipyretic effects primarily through central mechanisms. While its exact mechanism is not fully understood, it is thought to selectively inhibit prostaglandin synthesis in the central nervous system (CNS) by modulating cyclooxygenase (COX) enzymes, particularly COX-3, and by interacting with other neurotransmitter systems, such as the serotonergic and endocannabinoid pathways. Unlike NSAIDs, paracetamol exhibits weak peripheral anti-inflammatory activity. **Codeine** is an opioid analgesic that acts as a prodrug. It is metabolized in the liver, principally by the cytochrome P450 isoenzyme CYP2D6, to its active metabolite, morphine. Morphine acts as an agonist at mu-opioid receptors within the CNS and peripheral tissues, leading to a cascade of cellular events that inhibit the transmission of pain signals, alter the perception of pain, and induce euphoria and sedation. Codeine also possesses antitussive properties. **Caffeine** is a central nervous system stimulant. Its primary mechanism of action involves antagonizing adenosine receptors (A1 and A2A subtypes) in the brain. Adenosine typically acts as an inhibitory neurotransmitter; by blocking its receptors, caffeine promotes increased neuronal activity, leading to enhanced alertness and reduced fatigue. In combination with analgesics, caffeine is believed to augment their efficacy through various mechanisms, including cerebral vasoconstriction, direct analgesic effects, and potentiation of pain-relieving pathways, often contributing to a faster onset and greater magnitude of pain relief, particularly in headaches.